Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine.
Crystal
R G
RG
Rockefeller University Hospital, New York, New York 10021, USA.
Hirschowitz
E
E
Lieberman
M
M
Daly
J
J
Kazam
E
E
Henschke
C
C
Yankelevitz
D
D
Kemeny
N
N
Silverstein
R
R
Ohwada
A
A
Russi
T
T
Mastrangeli
A
A
Sanders
A
A
Cooke
J
J
Harvey
B G
BG
D000256:Adenoviridae / Q000235:genetics*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000963:Antimetabolites / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000473:pathology; D043525:Cytosine Deaminase; D004926:Escherichia coli / Q000201:enzymology / Q000235:genetics; D005260:Female; D005437:Flucytosine / Q000627:therapeutic use*; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy*; D008297:Male; D009700:Nucleoside Deaminases / Q000235:genetics; D011355:Prodrugs / Q000627:therapeutic use*; D014779:Virus Replication / Q000235:genetics
D000963:Antimetabolites; D011355:Prodrugs; D005437:Flucytosine; D009700:Nucleoside Deaminases; D043525:Cytosine Deaminase